Addex Therapeutics Ltd. cash flow statement

In fiscal 2025, Addex Therapeutics Ltd.'s operations generated −$2.6m of cash; it spent $0 on capital projects, leaving free cash flow of −$2.6m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Addex Therapeutics Ltd.: cash flow statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	2	−10	−13	−16	−17	−9	−6	−3
Depreciation and amortisation	0	0	0	0	0	0	0	0
Stock-based pay	2	2	1	1	4	2	1	0
Capital spending	0	0	0	0	0	0	0	0
Free cash flow	2	−10	−13	−16	−17	−9	−6	−3
Free cash flow after stock pay	−1	−11	−14	−17	−21	−11	−7	−3

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ADXN vs LYEL ADXN vs AIM ADXN vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Addex Therapeutics Ltd.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Addex Therapeutics Ltd.